Heterocyclic Building Blocks-Thiazole

Related Products of 6285-57-0In 2018, Kumari, Bhawana;Chauhan, Kalpana;Trivedi, Jalpa;Jaiswal, Varun;Kanwar, Shamsher S.;Pokharel, Yuba Raj published 《Benzothiazole-Based-Bioconjugates with Improved Antimicrobial, Anticancer and Antioxidant Potential》. 《ChemistrySelect》published the findings. The article contains the following contents:

Micro-organism resistance to the drugs has made it necessary to explore novel antibacterial drugs that have significant toxicities. Herein, we report the bioconjugates of N-acetyl-D-glucosamine with benzothiazole derivatives via ester linkage, which display potent effect against pathogenic micro-organisms (E. coli, S. aureus and C. albicans). These newly synthesized compounds have also been evaluated for anticancer (Hep-2 and caco cell lines) and antioxidant activities. The results supported that bioconjugates suppress pathogenic infections (in-vitro) more effectively in comparison to equivalent dosage of non-conjugated benzothiazole. Specifically, bioconjugates of Schiff derivative of methoxy-benzothiazol (compound 8) and nitro- benzothiazole (compound 9) showed MIC value of 1.25 μg/mL against C. albicans. The above proved potent compound 9, furthermore, revealed significant activity against Hep-2 and caco cell lines. In conclusion, this study proved that integration of biocomponent enhances the competence in biol. application and the results can be explored as a lead for further improvization for commercialization. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0) has been used:
as model analyte for voltammetric determination of electrochemically reducible organic substances;
in the synthesis of 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide derivatives;
in the preparation of push-pull nonlinear optical chromophores containing thiazole and benzothiazole acceptors;
as a base in dye production by diazotation reaction.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Formula: C7H5N3O2SIn 2022, Moodley, Rashmika;Mashaba, Chakes;Rakodi, Goitsemodimo H.;Ncube, Nomagugu B.;Maphoru, Mabuatsela V.;Balogun, Mohammed O.;Jordan, Audrey;Warner, Digby F.;Khan, Rene;Tukulula, Matshawandile published 《New Quinoline-Urea-BenzΞothiazole Hybrids as Promising Antitubercular Agents: Synthesis, In Vitro Antitubercular Activity, Cytotoxicity Studies, and In Silico ADME Profiling》. 《Pharmaceuticals》published the findings. The article contains the following contents:

A series of 25 new benzothiazole-urea-quinoline hybrid compounds, I (X = H, Me, F, NO₂, etc.) and II (n = 0, 2, 3, 4, and 6) were synthesized successfully via a three-step synthetic sequence involving an amidation coupling reaction as a critical step. In vitro evaluation of these hybrid compounds for their antitubercular inhibitory activity against the Mycobacterium tuberculosis H37Rv pMSp12::GPF bioreporter strain was undertaken. Of the 25 tested compounds, 17 compounds exhibited promising anti-TB activities of less than 62.5μM (MIC90) and 13 compds showed promising activity with MIC90 values in the range of 1-10μM, while compound I(X = CF₃), being the most active, exhibited sub-micromolar activity (0.968μM) in the CAS assay. In addition, minimal cytotoxicity against the HepG2 cell line (cell viability above 75%) in 11 of the 17 compounds, at their resp. MIC90 concentrations, was observed, with compound I(X = CF₃), exhibiting 100% cell viability. The hybridization of the quinoline, urea, and benzothiazole scaffolds demonstrated a synergistic relationship because the activities of resultant hybrids were vastly improved compared to the individual entities. In silico ADME predictions showed that the majority of these compounds have drug-like properties and are less likely to potentially cause cardiotoxicity (QPlogHERG > -5).6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) were involved in the experimental procedure.

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0Formula: C7H5N3O2S) has been shown to lower blood pressure in mice by inhibiting angiotensin converting enzyme and potassium channels. This drug also has a protective effect on the heart and brain from ischemia reperfusion injury.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Hedvat, Jessica;Salerno, David M.;Kovac, Danielle;Scheffert, Jenna L.;Corbo, Heather;Chen, Justin K.;Choe, Jason Y.;Jennings, Douglas L.;Anamisis, Anastasia;Liu, Esther C.;Lee, Jennifer H.;Shertel, Tara;Lange, Nicholas W. published 《Nitazoxanide treatment for norovirus infection in solid organ transplant recipients》. The research results were published in《Clinical Transplantation》 in 2022.Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate The article conveys some information:

A review. This was an IRB-approved, single-center retrospective study of all SOT recipients with GI PCR pos. for acute NV who either received nitazoxanide for NV or did not receive nitazoxanide between Jan., 2015 and August, 2019. A total of 195S OT recipients with GIPCR pos. for NV infection were screened; 52 patients who received nitazoxanide (nita+) were matched on the basis of transplant type and time post-transplant to 52 patients who had GIPCR pos. NV but did not receive nitazoxanide (nita-). These results suggest that nitazoxanide may improve symptoms from NV infection. To complete the study, the researchers used 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate (cas: 55981-09-4) .

2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate(cas: 55981-09-4), a thiazolide compound, is a antiparasitic drug with structure similar to niclosamide.Recommanded Product: 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Category: thiazole《Design, synthesis and biological evaluation of some 2-(6-nitrobenzo[d]thiazol-2-ylthio)-N-benzyl-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide derivatives as selective DprE1 inhibitors》 was published in 2019. The authors were Gawad, Jineetkumar;Bonde, Chandrakant, and the article was included in《Synthetic Communications》. The author mentioned the following in the article:

In the present study, pharmacophore model was developed using single ligand by ligand-based drug discovery approach. The key features responsible for DprE1 inhibitory activity were taken into consideration for developing pharmacophore. After the virtual screening, top 1000 hits were further subjected to docking study using GLIDE module, Schrodinger. Docking studies have shown promising interaction with amino residues with better glide score. Ligand-based drug design approach yielded a series of 15, 2-(6-nitrobenzo[d]thiazol-2-ylthio)-N-benzyl-N-(6-nitrobenzo[d]thiazol-2-yl)acetamide derivatives I(R¹ = H, Me, COMe, NH₂, etc.; R² = H, Br, NO₂, Me, etc.). The synthesized compounds were screened for In vitro antitubercular activity against Mycobacterium tuberculosis (H₃₇Rv). Four compounds, I (R¹ = H; R² = OMe) (MIC-1.01 μM); I (R¹ = Cl; R² = H) (MIC-0.91 μM); I (R¹ = R² = H) (MIC-0.82 μM); and I (R¹ = H; R² = Br) (MIC-1.04 μM) have shown promising activity compared to MIC of standard isoniazid (INH) and DprE1 enzyme inhibition was compared to BTZ043. Two halogen-substituted compounds have exhibited drastic enzyme inhibition. To complete the study, the researchers used 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0) has been used:
as model analyte for voltammetric determination of electrochemically reducible organic substances;
in the synthesis of 2-methyl-4-nitro-2H-pyrazole-3-carboxylic acid[2-(cyclohexanecarbonylamino)benzothiazol-6-yl]amide derivatives;
in the preparation of push-pull nonlinear optical chromophores containing thiazole and benzothiazole acceptors;
as a base in dye production by diazotation reaction.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica

Millet, Antoine;Filho, Mauro Safir;Hamouda-Tekaya, Nedra;Cavazza, Elisa;Abbe, Patricia;Ruediger, Johanna;Plaisant, Magali;Mayen, Julie;Rocchi, Stephane;Ronco, Cyril;Benhida, Rachid published 《Development and in vivo evaluation of fused benzazole analogs of anti-melanoma agent HA15》. The research results were published in《Future Medicinal Chemistry》 in 2021.Application In Synthesis of 6-Nitrobenzo[d]thiazol-2-amine The article conveys some information:

In line with our recent discovery of an efficient anticancer thiazolebenzenesulfonamide framework HA15 (1) based on a remarkable endoplasmic reticulum stress inducement mode of action, we report herein a series of innovative constrained HA15 analogs, featuring four types of bicylic derivatives The structure-activity relationship anal., using a cell line assay, led us to identify a novel version of HA15: a new benzothiazole derivative (10b) exhibiting important anti-melanoma effect against sensitive and resistant melanoma cells. Meanwhile, compound 10b induced a significant tumor growth inhibition in vivo with no apparent signs of toxicity. These results consistently open new directions to improve and develop more powerful anticancer therapeutics harboring this type of fused framework. The experimental procedure involved many compounds, such as 6-Nitrobenzo[d]thiazol-2-amine (cas: 6285-57-0) .

6-Nitrobenzo[d]thiazol-2-amine(cas:6285-57-0 Application In Synthesis of 6-Nitrobenzo[d]thiazol-2-amine) is an antimicrobial agent that inhibits bacterial growth by cleaving the peptide bonds of proteins. It has been shown to be active against a number of microorganisms, including Gram-positive and Gram-negative bacteria, as well as fungi.

Reference:
Thiazole | C3H3NS – PubChem,
Thiazole | chemical compound | Britannica